top of page

BioSpace 's article on uniQure's path for Huntington's gene therapy clouded by ethical questions as potential phase 3 looms.

katrina4384
Mar 7
1 min read
s
s

“To go back in a rare disease for sham surgeries is unethical,” Katie Jackson, president and CEO of Help 4 HD International, told BioSpace. “You’re asking people to get a sham surgery and sit in a placebo-like hold for one year, two years, three years,” preventing patients from participating in other clinical trials or from being able to receive AMT-130 in a future open-label extension study if they become too ill.


 
 
 

2 Comments


LaurenValdez
7 days ago

Since https://kritikeskazino.com keeps surfacing when I read about risk and fairness in high-stakes decisions, the sham surgery dilemma in this piece really stuck with me. Asking Huntington's patients to sit in a placebo hold for years while their condition progresses feels like a heavy price, and I keep wondering whether regulators and trial designers can find a middle ground that still produces solid data.

Like

Block Breaker
Nov 03

I like the quick gameplay in Drift Boss. There is no need to spend a long time learning complicated rules. Just focus on the corners, improve your timing, and see how far you can get.

Like

Subscribe Form

  • facebook
  • instagram
  • twitter

©2025 by Help 4 HD International.

bottom of page